Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32759358.
- Also identified by DOI 10.1158/1078-0432.CCR-20-1395 and PMC identifier 7785564.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The development of next-generation sequencing technology has dramatically improved our understanding of the genetic landscape of multiple myeloma. Several new drivers and recurrent events have been reported and linked to a potential driver role. This complex landscape is enhanced by intraclonal mutational heterogeneity and variability introduced through the dimensions of time and space. The evolutionary history of multiple myeloma is driven by both the accumulation of different genomic drivers and by the activity of different mutational processes active overtime. In this review, we describe how these new findings and sequencing technologies have been progressively allowed to understand and reshape our knowledge of the complexity of multiple myeloma at each of its developmental stages: premalignant, at diagnosis, and in relapsed/refractory states. We discuss how these evolutionary concepts can be utilized in the clinic to alter evolutionary trajectories providing a framework for therapeutic intervention at early-disease stages.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Medical Oncology
- Multiple Myeloma
- Precancerous Conditions
- Precision Medicine